In fact, several co-mutations associated with mutations in EGFR have been shown to bring about a lower efficacy to EGFR TKIs, to give tumor resistance to these molecules, and to result in a poorer prognosis [34,71,72,73,74,75]. This evidence concerns the gene EGFR and neoplasm.